PPD Confirms Takeda’s NDA Submission Of Alogliptin (highly Selective DPP-4 Inhibitor For The Treatment Of Type 2 Diabetes) In Japan
Oct 3rd 2008Drug InformationDiabetes
PPD, Inc. (NASDAQ:PPDI) today confirmed that Takeda Pharmaceutical Company Limited has submitted a new drug application for alogliptin, a highly selective DPP-4 inhibitor for the treatment of type 2 diabetes, to the Ministry of Health, Labour and Welfare in Japan. PPD partnered with Takeda to develop the compound.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
